Please login to the form below

Not currently logged in
Email:
Password:

Iron chelation may improve survival in MDS

Iron chelation therapy may significantly improve overall survival in heavily transfused patients with lower risk myelodysplastic syndrome (MDS)

A study published in the Leukaemia Research journal has concluded that iron chelation therapy (ICT) appears to improve survival in heavily transfused lower risk myelodysplastic syndromes (MDS) patients, and that adequate ICT was found significantly to improve overall survival in an independent manner.

In the multicentre study, 97 lower-risk (IPSS low and int-1 risk groups) regularly transfused MDS patients who received red blood transfusions, enrolled over a one-month period, were followed for 2.5 years. Data — on medical history, serum ferritin level at diagnosis and during follow up, and chelation therapy type (desferrioxamine deferasirox or deferiprone), tolerance, date of onset and termination, reasons for discontinuation, compliance, and impact on transfusion dependence and haematological characteristics — were collected and underwent multivariate analysis.

The team found that median survival for chelated patients was 10.3 years, compared with 4.4 years for non-chelated patients. This was a significant (p<0.0003) difference, more than doubling the overall survival in ICT-treated patients.

The positive effect of ICT on overall survival in other chronic anaemias, such as thalassemia major, is already established, though its benefits on MDS had previously only been suggested in small retrospective studies. However, current UK guidelines already recommend ICT in this patient population to avoid the possible toxic effects of iron overload (including damage to the heart, liver and endocrine system and death) caused by the repeated blood transfusions that are common among MDS patients. 

10th May 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics